# Evercore

Type: Company (EVR)

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/evercore
Canonical HTML page: https://gethealthbrief.com/entity/evercore

## Timeline

- **2026-08-19**: Press Release Distribution — Company issues PRNewswire release summarizing the summit highlights.
- **2026-08-18**: Evercore Summit Presentation — Antengene presents R&D updates including ATG-022 clinical data, TriGager TCE platform, multiple functional modules, and ATG-207 during a fireside chat.

## Recent coverage (2 stories)

### Antengene Unveils 2 TCE Platforms, ATG-207 at China Summit
2026-08-23 20:02:51 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

For healthcare executives and clinical leaders, Antengene's R&D showcase highlights emerging targeted oncology and autoimmune candidates. The presentation included updated ATG-022 data and a first-in-class bifunctional fusion protein, signaling pipeline expansion that could eventually affect treatment options. Clinical teams should note the data remain limited and are not yet peer-reviewed.
Full story: https://gethealthbrief.com/story/antengene-tce-platforms-atg207-evercore-summit-health

### Teva's $1.91-$2.11 EPS Guidance Misses Consensus, Testing Pharma Resilience
2026-08-05 14:16:51 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Teva Pharmaceutical's FY2026 EPS guidance fell short of the $2.17 consensus, while revenue projections of $16.5-$16.9B matched expectations. For healthcare leaders, the miss underscores ongoing generic drug pricing pressures and the importance of a diversified pipeline.
Full story: https://gethealthbrief.com/story/teva-fy2026-guidance-health

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.